Physician profile
Benson Grigsby
NPI 1487687513
$7,721.78
in general payments reported to CMS, 2019-2025
47 companies · $910 in 2025
The $910 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,139 · 2020: $1,108 · 2021: $1,366 · 2022: $1,169 · 2023: $1,272 · 2024: $758 · 2025: $910.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,920 · Education: $20.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,919.68 |
| Education | $20.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $904.43 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $749.40 | 2019-2025 | Breztri, Farxiga |
| Takeda Pharmaceuticals U.S.A., INC. | $709.63 | 2019-2025 | Trintellix |
| Novo Nordisk INC | $579.52 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $572.55 | 2019-2025 | |
| Amgen INC. | $521.59 | 2020-2025 | Repatha, Repatha, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $384.11 | 2022-2025 | |
| Lilly USA, LLC | $377.90 | 2020-2024 | Mounjaro, Jardiance |
| Teva Pharmaceuticals USA, INC. | $223.53 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $221.75 | 2019-2023 | Verquvo, Belsomra |
| Kowa Pharmaceuticals America, INC. | $185.06 | 2019-2022 | |
| Esperion Therapeutics, INC. | $174.73 | 2020-2023 | Nexletol |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $158.62 | 2020-2025 | Xifaxan |
| Astellas Pharma US INC | $147.30 | 2019-2024 | Veozah |
| Sanofi-Aventis U.S. LLC | $138.27 | 2019-2022 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benson Grigsby listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.